Articles tagged with Induced Pluripotent Stem Cells
Researchers at University of Copenhagen and University of Edinburgh identified 53 genes that regulate cell adhesion in embryonic stem cells. This new insight will enable scientists to maintain stem cells more effectively and efficiently manipulate adult cells to revert to a stem cell-like stage.
Researchers at the Weizmann Institute of Science have successfully created induced pluripotent stem cells (iPS cells) that can be kept in a pristine state, paving the way for growing transplant organs to order. The breakthrough enables the production of 'humanized' mouse models containing human-derived tissues.
Experts recommend approaches to standardize quality control, develop cost-effective sharing models, and create large-scale libraries of iPSC lines. These efforts aim to tap into the potential of iPSCs for drug screening, disease modeling, and medical treatments.
A new approach turns iPSCs into hematopoietic stem and progenitor cells, enabling blood disease-specific animal models. The technique overcomes technical barriers to generate engraftable cells needed for human patient models.
Researchers have discovered a process defective in patients with autosomal dominant polycystic kidney disease, a leading cause of kidney failure. Induced pluripotent stem cells from patients were reprogrammed to study human kidney disease mechanisms, revealing a potential therapeutic strategy by correcting a protein defect.
Researchers successfully grew vascular endothelial cells from human induced pluripotent stem cells, mimicking the flow of blood to differentiate cell types. The iPS-derived cells display critical functions carried out by mature endothelium in the body, including mounting inflammatory responses and preventing blood clots.
Researchers at the University of Pittsburgh School of Medicine have successfully regenerated a mouse heart using human heart precursor cells, paving the way for potential transplantation and drug testing models. The breakthrough could lead to personalized organ replacement and improved treatment options for heart disease patients.
The new approach has broad applicability for the successful production of iPSCs for use in human stem cell studies and eventual cell therapies. The method is highly reproducible, efficient, non-integrative, and works on both young and old human cells.
Researchers have successfully reprogrammed skin cells from patients with rare blood disorders, such as Diamond Blackfan anemia and juvenile myelomonocytic leukemia, into induced pluripotent stem cells (iPSCs). The iPSCs can be used to understand the underlying mechanisms of these diseases and test innovative treatments.
Researchers at the University of Toronto have developed a new method to mature human heart cells by applying electrical pulses and simulating fetal heart rates. This discovery offers a fast and reliable way to create mature human cardiac patches for various applications, including drug screening and transplantation.
Researchers from Japan created a human Dravet syndrome model using patient-derived induced pluripotent stem cells, revealing the effect of SCN1A mutations on GABAergic neurons. This breakthrough provides an unparalleled insight into the mechanism behind DS and a unique platform for drug development.
Scientists can now better study human disease using induced pluripotent stem cells (IPS), which can generate any cell type. This technology reduces the risk of organ/tissue rejection in cell transplants and allows for the correction of mutations in IPS cells.
Researchers developed a tunable process that separates human induced pluripotent stem cells (hiPSCs) based on their adhesive properties. The method allows for high-throughput separation and produces pure cultures with up to 99% hiPSC purity, enabling improvements in cell reprogramming and disease modeling.
Researchers at IUPUI have successfully differentiated human induced pluripotent stem cells into retinal cells using chemical methods, eliminating the need for animal products. This breakthrough could lead to new treatments for retinal diseases and expand the clinical use of regenerative human cells.
Using both familial and sporadic AD iPSCs, the researchers discovered that pathogenesis differed between individual AD patients. They found stress phenotypes associated with intracellular amyloid beta oligomers and attenuated these phenotypes with docosahexaenoic acid (DHA) treatment.
Researchers at Joslin Diabetes Center have successfully generated human induced pluripotent stem cells (hiPSCs) from patients with maturity onset diabetes of the young (MODY), a rare form of diabetes. The hiPSCs offer a powerful tool for studying the genetic mechanisms underlying MODY and testing potential treatments.
A Cedars-Sinai physician-scientist is leading a research study on Charcot-Marie-Tooth disease, the most common inherited neurological disorder, using induced pluripotent stem cells. The goal of the study is to determine if personalized stem cell lines can be generated for individual patients and potentially cure the disease.
Scientists at the University of Cambridge have developed a way to create induced pluripotent stem (iPS) cells from a routine blood sample. This method could lead to new treatments for cardiovascular diseases by using patients' own cells to repair damaged tissue.
Researchers at Boston University developed a novel technique to produce human induced pluripotent stem cells (iPSCs) from peripheral blood, offering an ethical alternative to embryonic stem cells. The method has been published in JoVE and provides a valuable resource for studying rare genetic disorders.
A new study by UC Davis researchers found that induced pluripotent stem cells (iPSCs) share significant similarities with malignant cancer cells, highlighting the need for caution in clinical use. The findings suggest that iPSCs could cause cancer and may require additional safety measures before they can be used to treat diseases.
Researchers at Mayo Clinic have developed a way to detect and eliminate potentially troublemaking stem cells, making stem cell therapy safer. The new approach uses a chemotherapeutic agent that selectively damages the DNA of the stem cells, efficiently killing the tumor-forming cells without affecting healthy ones.
Researchers found that Cell Banker 3 outperformed other cryopreservation solutions in preserving induced pluripotent stem (iPS) cell viability and proliferation. The solution allows iPS cells to be preserved for up to a year without significant loss of function.
Researchers at Salk Institute discover a unique molecular signature in induced pluripotent stem cells, consisting of nine genes that govern epigenetic changes. This finding could help overcome hurdles to using induced stem cells in regenerative medicine and provide a new understanding of their safety profile.
Researchers at Kyoto University's Center for iPS Cell Research and Application have successfully recreated ALS-associated abnormalities in motor neurons derived from patients' induced pluripotent stem cells. Anacardic acid was found to rescue certain ALS phenotypes in vitro, offering a promising lead for developing new drug treatments.
A new stem cell technique allows for efficient generation of abundant cardiomyocytes, critical heart muscle cells. This method is more efficient and robust than existing methods, promising a uniform alternative for research and pharmaceutical applications.
Researchers have successfully reprogrammed skin cells from elderly heart failure patients into healthy, beating heart muscle cells that can integrate with existing heart tissue. The study uses human-induced pluripotent stem cells (hiPSCs) to repair damaged hearts, offering a potential new treatment option for heart failure patients.
Researchers from Brazil and Korea used human immature dental pulp stem cells to create induced pluripotent stem cells, showing promising characteristics for therapeutic applications. The studies suggest that dental stem cells may be a valuable alternative source for regenerative medicine, including tooth regeneration and repair.
Researchers found relatively few genetic changes in induced pluripotent stem (iPS) cells derived from human bone marrow cells using an improved method. The study suggests that iPS cells do not pose a heightened cancer risk, but sequencing more cell lines is needed for a better understanding of mutation rates.
Researchers at RIKEN successfully developed a new experimental technique for producing cells with specific functions by reconstructing transcriptional regulatory networks. This technique enables faster and more efficient production of functional cells for cancer therapy and other applications.
Scientists at the University of Bonn have made a breakthrough in understanding Machado-Joseph disease by studying nerve cells derived from patients' skin cells. The research reveals that electrical activity in these cells triggers protein aggregation, explaining why the disease affects only nerve cells.
Researchers have discovered that lab-grown embryonic stem cells express the protein Blimp1, which represses differentiation and enables them to form cells of almost any type. This finding could help inform the development of induced pluripotent stem cells, a new type of stem cell derived from adult cells.
Researchers found almost no DNA structural mutations in induced pluripotent stem cells reprogrammed using a standard four-gene method. The study used advanced chromosomal error-mapping methods and detected only one mutation per line, which likely originated from the reprogramming process.
Researchers found Sox2 expression in various adult tissues, including stomach, testes, and cervix, confirming its status as a widespread marker of adult stem cells. These cells can give rise to all mature cell types in their respective tissues.
Researchers will use induced pluripotent stem cells and genome editing technology to recreate participants' own heart artery-lining cells in a dish. The goal is to understand how the 9p21 'gene desert' region contributes to heart disease.
A team of scientists used induced pluripotent stem cells from patients with inherited ALS to reveal how reduced VAPB protein levels contribute to the disease. The study provides a novel in vitro model of ALS and offers an unprecedented opportunity to answer questions about the disease's pathogenesis.
Researchers at UC San Diego found that induced pluripotent stem cells could be rejected by the immune system, challenging their potential as a promising means to develop stem cell therapies. The study suggests that iPSCs are subject to some of the same problems of immune system rejection as embryonic stem cells.
Scripps Research Institute investigators Joel Gottesfeld and Kristin Baldwin receive grants to explore stem cells' potential in biology and medicine. The funding supports studies on induced pluripotent stem cells, including methods to identify cancer-causing mutations and their impact on genetic diseases.
Researchers have found that mouse induced pluripotent stem (iPS) cells and embryonic stem (ES) cells produce highly similar definitive endoderm when differentiated in vitro. This suggests that iPS cells could be used for developing cell-based therapies for diseased endoderm-derived tissues.
Researchers have developed a new method to generate induced pluripotent stem cells (iPSCs) using microRNAs, increasing efficiency by 100-fold compared to traditional methods. This breakthrough has the potential to revolutionize regenerative medicine and tissue engineering.
Researchers have determined that correcting a genetic defect does not substantially increase the number of potentially cancer-causing mutations in induced pluripotent stem cells. This breakthrough suggests that human-induced pluripotent stem cells altered to correct a genetic defect may be cultured into subsequent generations of cells ...
Researchers discovered protein-coding point mutations in all 22 hiPSC lines, with an estimated six mutations per exome. The findings suggest that genetic screening of hiPSCs before clinical use is crucial to ensure their safety and accuracy.
Researchers have developed an approach to identify parasite genes associated with severe infection in pregnant women and children, offering new understanding of childhood malaria. Additionally, studies found that niacin can inhibit progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
Scientists found that hepatocyte-like cells derived from iPS cells exhibit 80% similar gene expression to those from embryonic stem cells, but less than that of real human liver cells. The study suggests that further adaptation is needed for iPSC-derived hepatocytes to be used in treating liver diseases.
Researchers found that adult cells from patients with Rett Syndrome could be transformed into induced pluripotent stem cells, which formed functional neurons in cell culture. However, these cells exhibited abnormalities that could be reversed by treating them with drugs, suggesting a potential therapeutic window before disease onset.
Researchers found that human embryonic stem cells and reprogrammed cells exhibit very few differences in gene expression signatures and are nearly indistinguishable in their chromatin state, according to Whitehead Institute researchers. This study suggests that reprogrammed cells may indeed hold clinical promise ascribed to them earlier.
Researchers have successfully established induced pluripotent stem (iPS) cells from dental pulp cells, a potential source for regenerative medicine. The study found that these cells can be easily obtained and expanded under simple culture conditions, making them an attractive option for cell therapy approaches.
Researchers at MGH-CRM and HSCI discovered that a key gene cluster is silenced in most iPSCs, limiting their developmental potential. However, some iPSC lines with the normal activation of this cluster were able to generate live animals, offering a promising approach for improving iPSC reprogramming.
A new strategy for reprogramming human adult cells into induced pluripotent stem (iPS) cells has been successfully developed, eliminating the need for oncogenes. This innovation offers improved safety and efficiency for producing patient-specific stem cells for therapeutic applications.
The NIH Common Fund has announced seven new scientific initiatives to tackle the toughest health problems facing the nation and the world. The programs focus on emerging science and technology advances in areas such as stem cells, protein capture, and global health.
Researchers use minicircles to reprogram adult cells, achieving higher efficiency than viral vectors and introducing new hope for regenerative medicine applications. The discovery enables easier creation of induced pluripotent stem cells, which can be used to study human diseases and develop novel treatments.
Researchers at the Genome Institute of Singapore have identified the genetic molecule Tbx3, which significantly improves the quality of induced pluripotent stem cells (iPS cells). The study successfully produced iPS cells that can recapitulate entire developmental processes and exhibit superior ability for germ-line transmission.
Bioethicists at Johns Hopkins University pose questions about the moral status of embryos created from induced pluripotent stem cells. The researchers advocate for clear ethical oversight to address concerns about the scientific achievement.
Scientists have reprogrammed mouse fibroblasts to create whole mice using tetraploid complementation, a significant advancement in understanding induced pluripotent stem cells. This achievement offers hope for overcoming embryo destruction in pluripotent cell derivation and potentially revolutionizing regenerative medicine.
Researchers successfully used induced pluripotent stem (iPS) cells to treat heart damage caused by infarction. The treatment restored heart muscle performance, stopped progression of structural damage, and regenerated tissue at the site of heart damage.
Researchers have successfully created pig stem cells using somatic cells from pigs with hooves, opening doors to creating models for human genetic diseases and developing resistant pigs. The discovery has far-reaching implications for animal and human health.
Researchers at Boston Children's Hospital have developed 20 disease-specific stem cell lines for conditions such as Parkinson's Disease, Down Syndrome, and Muscular Dystrophy. These lines were created using the iPS technique and will be made available to researchers worldwide.